13,000 Shares in Revvity, Inc. (NYSE:RVTY) Bought by Triodos Investment Management BV

Triodos Investment Management BV bought a new position in Revvity, Inc. (NYSE:RVTYFree Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 13,000 shares of the company’s stock, valued at approximately $1,421,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. bought a new stake in Revvity in the 3rd quarter valued at $1,579,487,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Revvity in the fourth quarter valued at about $188,368,000. Dimensional Fund Advisors LP acquired a new stake in Revvity during the fourth quarter worth about $112,037,000. Ceredex Value Advisors LLC acquired a new stake in Revvity during the fourth quarter worth about $108,353,000. Finally, Massachusetts Financial Services Co. MA bought a new position in Revvity during the fourth quarter valued at about $83,647,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Price Performance

Shares of NYSE:RVTY traded up $0.98 during trading on Tuesday, reaching $106.53. The stock had a trading volume of 858,003 shares, compared to its average volume of 830,971. The stock has a market capitalization of $13.14 billion, a PE ratio of 88.04, a P/E/G ratio of 2.73 and a beta of 1.09. Revvity, Inc. has a 52 week low of $79.50 and a 52 week high of $131.96. The business’s 50-day moving average price is $104.17 and its 200 day moving average price is $101.43. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.23 and a quick ratio of 1.92.

Revvity (NYSE:RVTYGet Free Report) last posted its quarterly earnings data on Monday, April 29th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04. The company had revenue of $649.90 million for the quarter, compared to analyst estimates of $646.83 million. Revvity had a return on equity of 7.37% and a net margin of 5.49%. The business’s revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.01 earnings per share. As a group, equities analysts predict that Revvity, Inc. will post 4.66 earnings per share for the current year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.26%. The ex-dividend date of this dividend is Friday, July 19th. Revvity’s payout ratio is presently 23.14%.

Analyst Ratings Changes

Several analysts have recently weighed in on RVTY shares. Robert W. Baird lifted their price objective on Revvity from $126.00 to $127.00 and gave the stock an “outperform” rating in a report on Tuesday, April 30th. UBS Group lowered shares of Revvity from a “buy” rating to a “neutral” rating and boosted their price target for the company from $105.00 to $125.00 in a report on Tuesday, January 16th. TD Cowen increased their price objective on shares of Revvity from $123.00 to $130.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Stifel Nicolaus lifted their target price on shares of Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a research report on Friday, February 2nd. Finally, Barclays increased their price target on shares of Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $118.17.

Get Our Latest Stock Report on RVTY

Revvity Profile

(Free Report)

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.

Recommended Stories

Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity, Inc. (NYSE:RVTYFree Report).

Institutional Ownership by Quarter for Revvity (NYSE:RVTY)

Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.